Medinol is a company that has been advancing the field of interventional cardiology since 1992 through in-house research, development, and manufacturing. They produce revolutionary products such as coronary and peripheral drug-eluting stents and are known for pushing the boundaries of medical innovation. Medinol's portfolio includes the EluNIR and EluNIR-PERL drug-eluting coronary stent systems, as well as investigational devices like the IoNIR, ChampioNIR, the Xemed valve for transcatheter aortic valve replacement (TAVR), and Microtech's sub-millimeter passive implantable sensors. Their commitment to clinical excellence is reflected in their global clinical trials and their Quality Management System, which ensures their products meet rigorous safety and efficacy standards. With the latest FDA approval for the EluNIR-PERL stent system, Medinol continues to contribute to the cutting-edge of cardiovascular intervention technologies.